Sign up to save your podcasts
Or
Share The Promise of AAV Gene Therapy with REGENXBIO's Ken Mills
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Promise of AAV Gene Therapy with REGENXBIO's Ken Mills
We love to hear from our listeners. Send us a message.
Ken Mills, CEO, President, and Director at REGENXBIO joins Erin Harris for this episode of Cell & Gene: The Podcast to discuss the company's progress with its Phase I/II Affinity Duchenne trial of RGX-202 for the treatment of Duchenne Muscular Dystrophy. They discuss the future of AAV gene therapy as well as achieving scalability with consistent yield and product purity in gene therapy manufacturing.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
View all episodes
By Erin Harris
4.9
3838 ratings
We love to hear from our listeners. Send us a message.
Ken Mills, CEO, President, and Director at REGENXBIO joins Erin Harris for this episode of Cell & Gene: The Podcast to discuss the company's progress with its Phase I/II Affinity Duchenne trial of RGX-202 for the treatment of Duchenne Muscular Dystrophy. They discuss the future of AAV gene therapy as well as achieving scalability with consistent yield and product purity in gene therapy manufacturing.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
More shows like Cell & Gene: The Podcast
View all
Nature Podcast
758 Listeners
HBR IdeaCast
177 Listeners
Planet Money
30,845 Listeners
Motley Fool Money
3,195 Listeners
Freakonomics Radio
32,299 Listeners
The Knowledge Project with Shane Parrish
2,648 Listeners
Immune
272 Listeners
The Readout Loud
318 Listeners
BioCentury This Week
29 Listeners
People I (Mostly) Admire
2,134 Listeners
Raising Health
147 Listeners
Biotech Hangout
18 Listeners
ASGCT Podcast Network
15 Listeners
NEJM AI Grand Rounds
54 Listeners
HBR On Leadership
155 Listeners